Neurolief, a neuroscience-driven medical technology company focused on non-invasive neuromodulation therapies, has secured a $6 million milestone-based investment from BrainsWay following FDA Premarket Approval of its ProlivRx system. The funding is intended to accelerate the U.S. rollout of the company’s at-home brain neuromodulation therapy designed for adults with major depressive disorder who have not achieved adequate response to at least one antidepressant.
ProlivRx, which received FDA approval in December 2025, is positioned as the first prescription neuromodulation system for depression that can be self-administered at home under physician supervision. The therapy aims to address a significant treatment gap for millions of patients whose symptoms persist despite medication, while overcoming access barriers to clinic-based neuromodulation treatments.
Traditional next-step depression therapies often require specialized facilities, creating logistical challenges such as referral delays and limited availability. Neurolief’s at-home model is designed to expand access by enabling patients to receive clinically supervised treatment without the need to travel to dedicated treatment centers.
The company said the new investment reflects growing demand for scalable, evidence-based mental health solutions as healthcare systems shift toward value-based care models. By enabling earlier intervention and reducing infrastructure constraints, ProlivRx is intended to help clinicians reach more patients efficiently.
BrainsWay, which invested in the company, is known for its Deep Transcranial Magnetic Stimulation platform and has multiple FDA-cleared indications across mental health and addiction disorders. The partnership underscores increasing industry momentum behind noninvasive neurostimulation technologies.
Neurolief plans to use the funding to expand commercial adoption of ProlivRx and further scale its delivery model, aiming to bring clinically validated neuromodulation therapy into everyday patient care settings.
KEY QUOTES
“This investment enhances our ability to bring clinically validated brain stimulation therapy to patients who have not achieved adequate improvement with antidepressants. ProlivRx was developed to close a critical access gap at a pivotal point in the depression care journey. With FDA approval and early commercial traction, we are scaling a model that delivers rigorous, evidence-based care in a way that is accessible and built for real-world adoption.”
Scott Drees, Chief Executive Officer, Neurolief
“As health systems shift toward value-based care, reaching high-need depression patients faster and more effectively is becoming increasingly critical. ProlivRx was developed with this reality in mind, delivering clinically supervised brain neuromodulation in the home, enabling clinicians to expand access, reduce treatment delays, and overcome the limitations of facility-based care.”
Owen Muir, MD, Chief Medical Officer, Neurolief
